Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG7667 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RG7667 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Single/multiple doses |
| RG7667 | DRUG | Single/multiple ascending doses |
Inclusion Criteria: * Male and female subjects, 18 to 55 years of age, inclusive * Body mass index 18.0 to 31.0 kg/m2, inclusive * In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs, and laboratory values, as deemed by the Investigator E...
RG7667 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease or condition it is intended to treat has not been publicly disclosed, and it remains in early clinical development.
RG7667 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program for this investigational small molecule.
RG7667 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational drug and has not been approved by the FDA for any indication.
RG7667 has been evaluated in a single Phase 1 trial, NCT01496755, titled "A Study of RG7667 in Healthy Volunteers." The trial was completed, enrolled 170 participants, and was conducted in the United States. It was randomized, double-blind, and placebo-controlled.
No, RG7667 is not FDA approved. It is an investigational small molecule in Phase 1 clinical development. The only completed trial was a Phase 1 study in healthy volunteers, and no regulatory approval has been granted for any indication.